Penumbra(US:PEN) ZACKS·2025-07-29 22:31Core Insights - Penumbra reported revenue of $339.46 million for the quarter ended June 2025, reflecting a year-over-year increase of 13.4% and surpassing the Zacks Consensus Estimate by 3.54% [1] - Earnings per share (EPS) for the quarter was $0.86, up from $0.64 in the same quarter last year, exceeding the consensus estimate of $0.81 by 6.17% [1] Financial Performance - The company's revenue from the United States was $260.82 million, a 19.5% increase compared to the previous year, and also above the average estimate of $257.86 million [4] - International revenue totaled $78.64 million, slightly above the average estimate of $70.83 million, but represented a year-over-year decline of 3.2% [4] - Revenue from Thrombectomy in the United States was reported at $188.53 million, closely aligning with the average estimate of $188.29 million [4] - The Embolization and Access segment in the United States generated $72.29 million, exceeding the average estimate of $69.57 million [4] - Total revenue from Embolization and Access was $109.2 million, significantly above the average estimate of $98.24 million, marking a year-over-year increase of 13.9% [4] - Thrombectomy revenue was reported at $230.26 million, slightly below the average estimate of $230.45 million, but still reflecting a year-over-year increase of 13.2% [4] Stock Performance - Over the past month, Penumbra's shares have decreased by 10.3%, contrasting with a 3.6% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]